NEXTBio Capital Management
NEXTBio Capital Management reported 22 stocks worth $217M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are PTGX (12.4%), STTK (11.9%) and CMPS (11.6%). Compared with Q1 2026, the fund opened new positions in PHVS, BIOA and LBRX, added to STTK, GPCR and RYTM, trimmed PTGX, CMPS and VOR and sold out of CMPX, OCS and SMMT.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 3 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  PTGX Protagonist Therapeutics Inc | $26.9M | 12.4% | 219K | −10K (−4%) | 3 of 3 | |
| 2 |  STTK Shattuck Labs Inc | $25.9M | 11.9% | 3.7M | +577K (+18%) | 3 of 3 | |
| 3 |  CMPS Compass Pathways PLC | $25.1M | 11.6% | 1.8M | −246K (−12%) | 3 of 3 | |
| 4 |  GPCR Structure Therapeutics Inc | $16.8M | 7.7% | 312K | +179K (+135%) | 3 of 3 | |
| 5 |  VOR Vor Biopharma Inc Com New | $16.4M | 7.5% | 889K | −111K (−11%) | 3 of 3 | |
| 6 |  RYTM Rhythm Pharmaceuticals Inc | $14.6M | 6.7% | 132K | +5,680 (+5%) | 3 of 3 | |
| 7 |  PVLA Palvella Therapeutics Inc NE | $13.7M | 6.3% | 90K | +7,223 (+9%) | 3 of 3 | |
| 8 |  XENE Xenon Pharmaceuticals Inc | $11.1M | 5.1% | 183K | No change | 3 of 3 | |
| 9 |  ZBIO Zenas Biopharma Inc | $10.8M | 5.0% | 427K | No change | 3 of 3 | |
| 10 |  ORIC Oric Pharmaceuticals Inc | $7.6M | 3.5% | 706K | +183K (+35%) | 3 of 3 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026
Reported value
last 3 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →NEXTBio Capital Management 13F FAQ
What does NEXTBio Capital Management own?
NEXTBio Capital Management reported 22 stocks worth $217M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are PTGX (12.4%), STTK (11.9%) and CMPS (11.6%). The table above lists every position in the filing (the top 10 without an account).
What did NEXTBio Capital Management buy and sell in Q2 2026?
Compared with Q1 2026: 3 new positions, 7 added to, 4 trimmed and 5 sold out. New positions include PHVS, BIOA and LBRX. It sold all of CMPX, OCS and SMMT.
When will NEXTBio Capital Management file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is NEXTBio Capital Management's portfolio worth?
The Q2 2026 filing reports $217M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.